Furthermore, blood concentrations of the evaluated marker in the treated JIA patients with no clinical improvement were significantly higher (p < 0.05), approximately by 62% as compared to serum YKL-40 concentrations in the treated remissive patients. This evidence concerns the gene CHI3L1 and juvenile idiopathic arthritis.